Compare Merck & Co., Inc. (MRK) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Merck & Co., Inc. trades at $146.21 (market cap $351.28B), while ProShares UltraPro Short QQQ ETF trades at $32.92 (market cap $2.23B). The key difference: Merck & Co., Inc. is far larger — about 157.5× ProShares UltraPro Short QQQ ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| MRK | SQQQ | |
|---|---|---|
Market Cap | $351.28B | $2.23B |
Volume | 7,969,665 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $89.43 |
52-Week Low | $82.49 | $31.83 |
Typical Hold Time | 98 Days | 12 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.02, up 2.93% on the day. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral momentum. As a 3x leveraged inverse ETF designed to profit from Nasdaq 100 declines, SQQQ's performance is directly tied to technology sector weakness. Recent news highlights its potential role as a hedging tool against QQQ holdings during market downturns.
The outlook for SQQQ depends heavily on technology sector performance, with potential gains during Nasdaq 100 declines but significant decay risk during sustained rallies. Investors face substantial volatility risks due to daily rebalancing and compounding effects. Current market conditions suggest continued uncertainty for tech stocks, potentially supporting SQQQ's short-term appeal as a tactical hedge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
